At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Modular, Phase II, Open-Label, Multicentre Study to Assess the Preliminary Efficacy and Safety of RXC004, in Patients With Advanced Solid Tumours That Have Progressed Following Therapy With Current Standard of Care
In Brief
A Phase 2 clinical trial evaluating RXC004, Denosumab, and 1 other intervention for Advanced Solid Tumours. Completed, enrolled 45 participants across 13 sites in 2 countries.
Detailed Summary
This study is to evaluate the preliminary efficacy and safety of RXC004 monotherapy and in combination with pembrolizumab in advanced solid tumours that have progressed following SoC treatment.
Study Details
Timeline
Interventions
RXC004 will be administered orally, 2 mg QD; Dose Formulation: 0.5 mg or 1 mg capsules.
RXC004 will be administered orally, 2 mg QD (Cohort 1, Module 2) and 1 mg QD (Cohort 2, Module 2); Dose Formulation: 0.5 mg or 1 mg capsules.
RXC004 will be administered orally, 1.5 mg QD; Dose Formulation: 0.5 mg or 1 mg capsules.
Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month; Use: Prophylactic
Pembrolizumab will be administered via intravenous infusion, 400 mg dose once every 6 weeks